Sunny Bush, NP
Nurse Practitioner · Santa Rosa
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Offices
- 2
- Since medical school
- 8 years
- Graduated 2018
Offices
2 locations · Siyan Clinical Corporation · County of Sonoma
Looking this up.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Sunny Bush’s office at (707) 565-4861 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Original Medicare doctor bills
$18,853
Medicare paid this office $18,853 for 38 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 31 | $11,990 | $89 |
| Psychotherapy with evaluation and management visit, 30 minutes | 23 | $3,703 | $50 |
| Psychotherapy with evaluation and management visit, 45 minutes | 14 | $1,476 | $64 |
Who their Medicare patients are
38 Original Medicare patients in 2024. Average age 71 · Women 68% · Health risk score 1.01. At or below the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: Depression 68% · High blood pressure 47%.
The office billed $52,695, Medicare allowed $24,578 and paid $18,853; for 269 services of 8 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 38 | 269 | 71 | 1.01 | $52,695 | $18,853 |
| 2023 | 19 | 206 | 68 | 0.97 | $39,045 | $11,230 |
| 2022 | 21 | 215 | 70 | 0.93 | $41,845 | $13,660 |
| 2019 | 18 | 38 | 45 | 1.25 | $9,325 | $3,995 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Return visit (30+ min) | 16 | $7,692 | $73 |
| Psychotherapy with evaluation and management visit, 30 minutes | 15 | $2,392 | $43 |
2022: 2 services
| Return visit (30+ min) | 20 | $7,716 | $80 |
| Psychotherapy with evaluation and management visit, 30 minutes | 17 | $3,103 | $47 |
2019: 1 service
| Return visit (30+ min) | 16 | $1,196 | $70 |
Medicaid work
$10,894 in 2024
Medicaid paid $10,894 for 91 billed services this clinician did in 2024, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 91 | $10,894 |
| 2024 | 91 | 1 | 16 | $10,894 |
Drugs they prescribed that Part D paid
$41,695
Pharmacies billed $41,695 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 735) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
708 generic and 27 brand-name prescriptions · $41,695 in drug cost · 52 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Vraylar | 11 | $15,637 | $1,422 |
| Bupropion Xl | 58 | $2,960 | $51 |
| Vilazodone | 16 | $1,634 | $102 |
| Amitriptyline | 57 | $1,116 | $20 |
| Gabapentin | 88 | $878 | $10 |
See all 21 drugs
| Vraylar | 11 | $15,637 | $1,422 |
| Bupropion Xl | 58 | $2,960 | $51 |
| Vilazodone | 16 | $1,634 | $102 |
| Amitriptyline | 57 | $1,116 | $20 |
| Gabapentin | 88 | $878 | $10 |
| Trazodone | 46 | $599 | $13 |
| Quetiapine | 42 | $576 | $14 |
| Duloxetine | 24 | $548 | $23 |
| Venlafaxine Hcl Er | 23 | $547 | $24 |
| Lamotrigine | 30 | $543 | $18 |
| Aripiprazole | 33 | $336 | $10 |
| Dextroamphetamine-Amphetamine | 23 | $334 | $15 |
| Mirtazapine | 20 | $295 | $15 |
| Desvenlafaxine Succinate Er | 19 | $261 | $14 |
| Buspirone | 19 | $254 | $13 |
| Propranolol | 21 | $246 | $12 |
| Baclofen | 14 | $175 | $13 |
| Divalproex | 16 | $155 | $10 |
| Clonazepam | 31 | $121 | $4 |
| Chlordiazepoxide | 12 | $83 | $7 |
| Alprazolam | 20 | $60 | $3 |
Year by year
| 2024 | 735 | 58 | 0% (0) | 4% | $41,695 |
| 2023 | 859 | 55 | 0% (0) | 2% | $37,396 |
| 2022 | 482 | 52 | 0% (0) | None | $19,807 |
| 2021 | 335 | 37 | 0% (0) | None | $16,592 |
| 2020 | 175 | 28 | 0% (0) | None | $8,926 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 21 drugs
| Olanzapine | 45 | $4,598 | $102 |
| Venlafaxine Hcl Er | 35 | $1,843 | $53 |
| Trazodone | 45 | $1,611 | $36 |
| Gabapentin | 93 | $1,565 | $17 |
| Bupropion Xl | 45 | $1,444 | $32 |
| Divalproex | 22 | $1,308 | $59 |
| Prazosin | 20 | $1,301 | $65 |
| Quetiapine | 77 | $1,195 | $16 |
| Amitriptyline | 76 | $1,105 | $15 |
| Mirtazapine | 45 | $627 | $14 |
| Aripiprazole | 37 | $537 | $15 |
| Dextroamphetamine-Amphetamine | 29 | $527 | $18 |
| Duloxetine | 31 | $508 | $16 |
| Propranolol | 14 | $384 | $27 |
| Lamotrigine | 26 | $384 | $15 |
| Hydroxyzine | 18 | $324 | $18 |
| Clonazepam | 37 | $226 | $6 |
| Escitalopram | 15 | $179 | $12 |
| Alprazolam | 30 | $169 | $6 |
| Chlordiazepoxide | 13 | $65 | $5 |
| Fluoxetine | 11 | $43 | $4 |
2022: 15 drugs
| Duloxetine | 16 | $2,628 | $164 |
| Bupropion Xl | 32 | $2,509 | $78 |
| Venlafaxine Hcl Er | 21 | $1,803 | $86 |
| Aripiprazole | 23 | $870 | $38 |
| Amitriptyline | 27 | $767 | $28 |
| Gabapentin | 47 | $725 | $15 |
| Quetiapine | 38 | $665 | $17 |
| Olanzapine | 16 | $657 | $41 |
| Trazodone | 34 | $607 | $18 |
| Dextroamphetamine-Amphetamine | 12 | $431 | $36 |
| Hydroxyzine | 15 | $323 | $22 |
| Clonazepam | 39 | $307 | $8 |
| Escitalopram | 14 | $193 | $14 |
| Lamotrigine | 20 | $170 | $9 |
| Alprazolam | 16 | $155 | $10 |
2021: 11 drugs
| Buprenorphine-Naloxone | 21 | $7,111 | $339 |
| Venlafaxine Hcl Er | 23 | $962 | $42 |
| Aripiprazole | 24 | $853 | $36 |
| Bupropion Xl | 21 | $664 | $32 |
| Dextroamphetamine-Amphetamine | 14 | $515 | $37 |
| Gabapentin | 30 | $378 | $13 |
| Trazodone | 29 | $345 | $12 |
| Clonazepam | 43 | $338 | $8 |
| Quetiapine | 16 | $223 | $14 |
| Hydroxyzine | 11 | $105 | $10 |
| Escitalopram | 12 | $79 | $7 |
2020: 6 drugs
| Buprenorphine-Naloxone | 45 | $6,096 | $135 |
| Duloxetine | 17 | $793 | $47 |
| Bupropion Xl | 11 | $217 | $20 |
| Trazodone | 19 | $150 | $8 |
| Clonazepam | 12 | $93 | $8 |
| Quetiapine | 12 | $86 | $7 |
Money from drug and device companies
$811 in 2025
| 2025 | 9 | 35 | None | $811 |
| 2024 | 12 | 32 | None | $641 |
| 2023 | 9 | 36 | None | $740 |
| 2022 | 9 | 39 | None | $703 |
| 2021 | 6 | 25 | None | $433 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Teva Pharmaceuticals USA | Uzedy | $194 | 5 payments
|
| Abbvie | Vraylar | $190 | 11 payments
|
| Otsuka America Pharmaceutical | Rexulti | $129 | 5 payments
|
| Lundbeck | Abilify Asimtufii | $94 | 4 payments
|
| Alkermes | Aristada | $54 | 2 payments
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $49 | 3 payments
|
See all 35 published payments
| Otsuka America Pharmaceutical | Meals · 2025-11-06 | Rexulti | $31 |
| Teva Pharmaceuticals USA | Meals · 2025-10-08 | Uzedy | $39 |
| Indivior | Meals · 2025-09-10 | Sublocade | $22 |
| Otsuka America Pharmaceutical | Meals · 2025-08-26 | Rexulti | $27 |
| Abbvie | Meals · 2025-07-30 | Vraylar | $25 |
| Lundbeck | Meals · 2025-07-09 | Rexulti | $21 |
| Indivior | Meals · 2025-07-01 | Sublocade | $22 |
| Axsome Therapeutics | Meals · 2025-06-25 | Auvelity | $22 |
| Abbvie | Meals · 2025-06-18 | Vraylar | $23 |
| Alkermes | Meals · 2025-06-10 | Aristada | $27 |
| Otsuka America Pharmaceutical | Meals · 2025-05-21 | Rexulti | $24 |
| Abbvie | Meals · 2025-05-14 | Vraylar | $22 |
| Teva Pharmaceuticals USA | Education · 2025-05-14 | None | $100 |
| Teva Pharmaceuticals USA | Meals · 2025-05-07 | Uzedy | $13 |
| Teva Pharmaceuticals USA | Meals · 2025-05-06 | Uzedy | $2 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-04-25 | Caplyta | $20 |
| Abbvie | Meals · 2025-04-23 | Vraylar | $10 |
| Otsuka America Pharmaceutical | Meals · 2025-04-22 | Rexulti | $27 |
| Almatica Pharma | Meals · 2025-04-16 | Loreev Xr | $16 |
| Abbvie | Meals · 2025-04-11 | Vraylar | $22 |
| Lundbeck | Meals · 2025-04-08 | Rexulti | $24 |
| Abbvie | Meals · 2025-04-02 | Vraylar | $23 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-03-26 | Caplyta | $15 |
| Abbvie | Meals · 2025-03-20 | Vraylar | $9 |
| Otsuka America Pharmaceutical | Meals · 2025-03-19 | Rexulti | $20 |
| Axsome Therapeutics | Meals · 2025-03-12 | Auvelity | $18 |
| Abbvie | Meals · 2025-03-06 | Vraylar | $23 |
| Alkermes | Meals · 2025-03-01 | Aristada | $27 |
| Abbvie | Meals · 2025-02-19 | Vraylar | $8 |
| Lundbeck | Meals · 2025-02-19 | Abilify Asimtufii | $28 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-02-10 | Caplyta | $15 |
| Teva Pharmaceuticals USA | Meals · 2025-02-05 | Uzedy | $41 |
| Abbvie | Meals · 2025-01-22 | Vraylar | $16 |
| Lundbeck | Meals · 2025-01-14 | Abilify Asimtufii | $21 |
| Abbvie | Meals · 2025-01-06 | Vraylar | $8 |
See earlier years (2024, 2023, 2022, 2021)
2024: $641
| Abbvie | Vraylar | $247 | 15 payments
|
| Indivior | Sublocade | $92 | 3 payments
|
| Lundbeck | Abilify Asimtufii | $47 | 2 payments
|
| Teva Pharmaceuticals USA | Uzedy | $43 | 2 payments
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $41 | 2 payments
|
| Janssen Pharmaceuticals | Invega Sustenna | $40 | 2 payments
|
| Bausch Health US | Aplenzin | $27 | 1 payment
|
| Neurocrine Biosciences | Ingrezza | $24 | 1 payment
|
| Alkermes | Aristada | $21 | 1 payment
|
| Corium | Azstarys | $21 | 1 payment
|
| Otsuka America Pharmaceutical | Rexulti | $21 | 1 payment
|
| Axsome Therapeutics | Auvelity | $18 | 1 payment
|
2023: $740
| Abbvie | Vraylar | $215 | 11 payments
|
| Neurocrine Biosciences | Ingrezza | $121 | 6 payments
|
| Alkermes | Aristada | $118 | 6 payments
|
| Otsuka America Pharmaceutical | Rexulti | $66 | 3 payments
|
| Bausch Health US | Aplenzin | $63 | 3 payments
|
| Axsome Therapeutics | Auvelity | $59 | 2 payments
|
| Lundbeck | Abilify Maintena | $46 | 2 payments
|
| Iti | Caplyta | $36 | 2 payments
|
| Indivior | Sublocade | $16 | 1 payment
|
2022: $703
| Abbvie | Vraylar | $291 | 17 payments
|
| Alkermes | Aristada | $100 | 5 payments
|
| Bausch Health US | Aplenzin | $100 | 5 payments
|
| Iti | Caplyta | $81 | 4 payments
|
| Teva Pharmaceuticals USA | Austedo | $43 | 2 payments
|
| Neurocrine Biosciences | Ingrezza | $37 | 2 payments
|
| Lundbeck | Abilify Maintena | $18 | 1 payment
|
| Otsuka America Pharmaceutical | Abilify Maintena | $18 | 1 payment
|
| Sunovion Pharmaceuticals | Latuda | $15 | 2 payments
|
2021: $433
| AbbVie | Vraylar | $282 | 17 payments
|
| Lundbeck | Rexulti | $55 | 3 payments
|
| Neurocrine Biosciences | Ingrezza | $42 | 2 payments
|
| Indivior | Sublocade | $21 | 1 payment
|
| Otsuka America Pharmaceutical | Rexulti | $19 | 1 payment
|
| Sunovion Pharmaceuticals | Latuda | $14 | 1 payment
|
Professional record
- NPI
- 1548723422
- Licence
- CA 95013998
- Group
- Siyan Clinical Corporation · County of Sonoma
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Nurse practitioner (363L00000X)
- Mailing address
- 480 Tesconi Cir Ste B, Santa Rosa, CA, 95401
- NPI first listed
- 2019-04-09
- NPI last updated
- 2020-04-03
- NPI record certified
- 2020-04-03
This is when the NPI record was last certified, not a medical board exam.